Jiudian Pharmaceutical: plans to use its own funds of RMB 46.5845 million to acquire 10% equity in Nona Medicine held by Shangshan Hongren.

Jiudian Pharmaceutical announced that it plans to use its own funds of 46.5845 million yuan to acquire 10% of the equity in Nona Pharmaceutical held by Shangshan Hongren. After this transaction is completed, the company's shareholding in Nona Pharmaceutical will increase from 60% to 70%. Nona Pharmaceutical will remain a subsidiary of the company and will continue to be included in the consolidated financial statements.